17 days before the patent expires, pharmaceutical company lowers the price of Rybelsus and offers free dose of Wegovy
Novo Nordisk has announced a significant price reduction for its medications Rybelsus and Wegovy, ahead of the expiration of the patent for Ozempic.
Novo Nordisk will invest 432 million in the Irish factory of the Wegovy pill to grow outside the US
Novo Nordisk is investing 432 million euros in its Irish factory to boost production of the Wegovy weight loss pill for markets outside the United States.
First battle of the 'Ozempic' pill: Lilly's tablet outperforms Novo Nordisk's
Lilly's anti-obesity pill, orforglipron, shows better results than Novo Nordisk's semaglutide in controlling blood sugar and weight for type 2 diabetes patients, despite higher discontinuation rates due to side effects.
Novo Nordisk: Reducing drug prices for obesity and diabetes by 50% in the USA
Novo Nordisk has announced a 50% reduction in the prices of its obesity and diabetes medications in the USA, effective January 2027.
The prices of Ozempic and Wegovy will drop by up to half – but not everyone will benefit
Novo Nordisk announced that the prices of popular weight loss drugs Ozempic and Wegovy will significantly decrease starting in 2027, with Wegovy becoming half as expensive and Ozempic a third less expensive for all patients.
Secret negotiations could lead to cheaper obesity medicine – and a victory for the government
The Danish government is negotiating with Novo Nordisk to potentially subsidize obesity medication for patients, which could alleviate financial burdens on those with prescriptions.
Novo Nordisk will halve the price of its anti-obesity drug Wegovy in the United States starting in 2027
Novo Nordisk announced a plan to reduce the price of its anti-obesity drug Wegovy by 50% in the U.S. starting in 2027 to improve affordability and competitiveness.
Novo Nordisk Reduces List Price of Wegovy in the USA by Half
Novo Nordisk has announced a significant reduction in the list prices of its drugs, including Wegovy, Ozempic, and Rybelsus, effective January 2027.
Novo on the way with a new weight loss drug
Novo Nordisk has released data from a study on a weight loss drug developed in collaboration with Chinese company United Biotechnology, showing significant weight loss among participants.
Novo Nordisk's shares plummet more than 16% after results of new drug
Novo Nordisk's shares sharply declined following disappointing clinical trial results of its new weight-loss drug, CagriSema, which underperformed compared to a competitor's product.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk's new weight-loss drug, CagriSema, has been deemed 'obsolete' after disappointing clinical trials, leading to a significant drop in the company's shares.
No to subsidies for obesity medication
The Swedish Dental and Pharmaceutical Benefits Agency has rejected a subsidy application for the obesity medication Wegovy from Novo Nordisk.
Novo Nordisk: 15% Drop in Stock - Why the Clinical Trial of CagriSema Was Disappointing
Novo Nordisk's stock plummeted 15% after its new drug CagriSema failed to meet key weight-loss targets in a clinical trial compared to Eli Lilly's tirzepatide.
Novo Nordisk sinks again on the stock market after failing trials for its new obesity drug
Novo Nordisk's shares dropped significantly after the company reported failures in trials for its experimental obesity drug, CagriSema.
Business Ticker: Novo Nordisk shares fall by 11 percent – set back with weight loss drug
Novo Nordisk shares have dropped by 11 percent due to setbacks related to its weight loss medication.
Novo Nordisk stock closes at lowest price since 2021
Novo Nordisk's stock dropped over 16%, closing at its lowest since June 2021, following disappointing results from a weight-loss study.
Novo Nordisk Stock Falls After New Data on Weight Loss Hope
Novo Nordisk's stock drops following the release of new study data on the company's weight loss drug, Cagrisema, which showed a 23% weight loss over 84 weeks.
Legal Dispute Over Weight Loss Drugs: Ozempic Manufacturer Accuses Competitor of Selling Dangerous Product
Danish pharmaceutical company Novo Nordisk has sued American company Hims & Hers, accusing it of selling an 'unsafe' copy of its weight loss drug.
Medical advances will be for those who can afford them
The article discusses the recent advancements in obesity medications and the challenges of making them accessible to the broader population.
Five municipalities join forces to help laid-off Novo employees
Five municipalities in Denmark are collaborating to assist former Novo Nordisk employees in finding new jobs after receiving funding from the Ministry of Employment.
Novo to respond to concerns about misleading TV advertisement
Novo Nordisk is preparing a response to the FDA over concerns regarding a misleading TV advertisement for its Wegovy weight-loss pill.
Novo is working on a response to the FDA after a letter about misleading Wegovy advertisement
Novo Nordisk is preparing a response to the FDA regarding a letter that stated an advertisement for its Wegovy pill was misleading or false.
Reacting to Novo Nordisk's lawsuit: An attack on millions of Americans
Hims & Hers has responded to Novo Nordisk's patent infringement lawsuit, calling it an attack on American consumers after launching a non-approved version of the drug Wegovy.
Novo sues American competitor for selling copy medicine
Novo Nordisk is suing an American competitor to stop the sale of copies of its weight loss and diabetes medications in the USA and to seek compensation for losses.
Novo Nordisk: Frenzied rally after the withdrawal of a weight loss drug
Novo Nordisk's stock surged approximately 8% following Hims & Hers's decision to withdraw a low-cost weight loss pill similar to Wegovy amid legal threats from both Novo Nordisk and the FDA.
Novo Nordisk Stock Rises After Cancellation of Copy Pill
Novo Nordisk's stock rose significantly after Hims and Hers announced they would not sell a generic version of Wegovy.
Copy pill withdrawn - now Novo stock rises
Novo Nordisk's stock has risen by eight percent following the withdrawal of a competing weight loss drug by online pharmacy Hims & Hers due to regulatory issues.
Sote Minister Juuso Acquires Shares in Pharmaceutical Company – Now There’s an Explanation
Finland's Social and Health Minister Kaisa Juuso has acquired shares in the pharmaceutical company Novo Nordisk, raising questions about potential conflicts of interest in her ministerial duties.
Expert after turbulent week: "It is a huge plus for Novo Nordisk"
Despite facing competition from cheaper alternatives, Novo Nordisk's reputation has strengthened following a recent turbulent week.
Millions on the way to help former Novo employees
The Danish government is allocating 13 million kroner to support municipalities in helping former employees of Novo Nordisk find new jobs after mass layoffs.
American company gives up the sale of Wegovy copy
The American telehealth company Hims and Hers has decided to cease the sale of a copy of Novo's weight loss medication Wegovy after discussions with industry stakeholders.
Novo competitor stops the supply of copy medicine
The company Hims and Hers has decided to stop offering a cheaper copy of Novo Nordisk's weight loss drug Wegovy.
Copy of Wegovy pill withdrawn
The company Hims and Hers has ceased offering its cheaper copy of Novo Nordisk's weight loss medication Wegovy after constructive talks with stakeholders.
Daily Summary #1851: Fachin cancels meeting to discuss STF Code of Ethics; Pharmaceutical requests authorization to sell Wegovy in pill form; Risks of mixing vodka with energy drink during carnival
The daily summary highlights key events including Fachin's cancellation of a meeting to discuss the STF Code of Ethics, a request from Novo Nordisk for authorization to sell Wegovy in Brazil, and concerns over the health risks of mixing vodka and energy drinks during carnival.
The telehealth company Hims takes on Novo Nordisk with its own version of Wegovy for $49 per month, a third of its rival's price
Telehealth company Hims & Hers Health is launching a new weight-loss pill at $49 a month, competing directly with Novo Nordisk's Wegovy, which contains the same active ingredient.
Eli Lilly or Novo Nordisk? The stock market has mercilessly decided
The market for weight-loss injections is expanding, but investors have decisively favored one pharmaceutical giant over the other.
Novo Nordisk calls competitors' copies illegal
Novo Nordisk criticizes Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, claiming it poses significant risks to patient safety and threatens its intellectual property, prompting plans for legal action.
Novo Nordisk strongly criticizes competitor
Novo Nordisk has issued a sharp condemnation of Hims and Hers for planning to launch a copy of the weight loss drug Wegovy, labeling it as illegal mass production that jeopardizes patient safety, and announcing intentions to take legal and regulatory action.
New stock market drop for Novo after copy of new Wegovy pill
Danish pharmaceutical company Novo Nordisk's stock plummeted after the launch of a cheaper version of its Wegovy pill by US firm Hims and Hers.
New dive in stocks after competitor's launch
Danish pharmaceutical company Novo Nordisk experiences a sharp drop in stock prices following the launch of a competing weight loss pill by Hims and Hers.
Novo Nordisk requests Anvisa's authorization to sell Wegovy in pills in Brazil
Novo Nordisk has requested authorization from Anvisa to sell Wegovy in pill form in Brazil, with the request submitted on January 30, but the Brazilian regulatory agency has not yet responded.
How the drugs that will revolutionize obesity treatment work
Semaglutide by Novo Nordisk is the first drug approved for obesity treatment that achieves weight loss comparable to bariatric surgery, while Eli Lilly's tirzepatide is expected to gain approval soon after showing efficacy and safety in clinical trials.
Patients Receive Compensation for Eye Disease After Use of Novo Products
11 patients are receiving compensation for the serious eye disease NAION due to the use of Novo Nordisk medications Wegovy and Ozempic, as revealed by new statistics from the Patient Compensation Association.
11 patients receive compensation for eye disease after using Novo drugs
An increasing number of patients are receiving compensation for the serious eye disease NAION caused by the use of Novo Nordisk's drugs Wegovy and Ozempic, with 67 patients having sought compensation so far.
Weight Loss Injections: Novo Nordisk Predicts "Shocking" Sales Decline
Novo Nordisk warns of a significant decline in revenue due to increased competition and low prices in the U.S. despite rising prescriptions for its new Wegovy pill.
Novo Nordisk has never made as much money as now – so why is the stock diving?
Despite record sales of its popular weight loss medication and a profit of 102 billion kroner, investors are fleeing from Novo Nordisk.
"The market is relatively saturated - we see no big growth prospects anymore"
Danish pharmaceutical company Novo Nordisk has shocked investors with an unexpectedly gloomy outlook for 2026, causing its stock to plummet, as explained by market expert Andreas Lipkow in an interview.
Novo Nordisk crashes in stock market after lowering sales forecast for Ozempic, its star drug
Danish pharmaceutical company Novo Nordisk's stock plummeted up to 17% in Copenhagen after it lowered sales and profit forecasts for 2026 due to increased competition for its flagship drug, Ozempic.
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk, the maker of Wegovy and Ozempic, expects a significant revenue decline this year due to competition, patent expirations, and price reductions influenced by Donald Trump's policies.
Novo Nordisk's shares plummet amid strong sales forecast drop for Ozempic and Wegovy this year
Novo Nordisk's stock fell by up to 20% following a forecast predicting a significant decline in sales for its weight loss drugs Ozempic and Wegovy, resulting in a 13% revenue cut for 2026.